Evaluation of Computed Tomography Scan and CA 125 Response in Predicting Operability in Advanced Ovarian Cancer and Assessing Survival Outcome in Interval Cytoreductive Surgery
- 2 Downloads
The study aims at the prediction of optimal cytoreduction (OCR) in patients undergoing interval cytoreduction (ICR) in advanced epithelial ovarian cancer (AEOC) based on CT imaging and CA 125 values and assessing the survival pattern of these patients after ICR. This is a prospective observational study of patients with stage III C ovarian cancer who underwent ICR in our institution after neoadjuvant chemotherapy (NACT). All consecutive patients operated from April 2016 to October 2017 were included in the study. From their medical records, their demographic details and clinical variables were recorded. The CA 125 value and CT scan findings before and after chemotherapy were documented. A Bristow’s predictive score (BS) was calculated based on the radiological parameters. After ICR, the outcome of the surgery was documented. Optimal cytoreduction (OCR) was defined as no gross residual disease after surgery. The surgical outcome was correlated with the CA 125 difference pre and post chemotherapy and Bristow’s predictive score pre and post chemotherapy. The patients were followed up and their survival at 6 and 12 months was assessed. Univariate and multivariate analysis was done to identify factors predicting OCR. 51 patients were included in the study. Age group of the women ranged from 31 to 74 years with a mean of 52 years. Majority of the patients (70.6%) were postmenopausal. Of the 51 women, OCR could be achieved in 31 patients (60.8%). Post-chemotherapy, 36 patients had elevated CA125 above baseline of which 50% attained OCR. Forty six patients had CA 125 response post chemotherapy of which 67.4% attained OCR. Forty five patients had reduction in Bristow Score compared to the pre chemo values of which 64.4% attained OCR which was not found to be statistically significant. Overall survival was 100% survival at 6 months and 92.8% at 12 months in those who achieved OCR. Those with residual disease 0.1–1 cm had survival of 74.1% at 6 and 12 months. Those with residual disease > 1 cm had a survival of 50% at 6 and 12 months. CA125 response has a significant role in predicting OCR while CT evaluation using the BS was not useful in predicting OCR during ICR for AEOC.
KeywordsOvarian cancer CA 125antigen, CT scan Cytoreduction surgical procedure Survival analysis
I would like to express my sincere gratitude to my supervisors Dr. P Rema, Dr. Anil Prahladan and Dr. Suchetha Jyothish for providing their invaluable guidance, comments and suggestions throughout the conduct of this study. I would specially thank Dr. Preethi George for her assistance in the data analysis. Also, I would like to thank Dr. Aswathy and Dr. Vijayshanti for their help during the preparation of the sample and data collection.
This work described has not been published before and it is not under consideration for publication anywhere. Its publication has been approved by all its authors.
Conceptualization: Elizabeth Reshmi John,P Rema.
Methodology: P Rema, Elizabeth Reshmi John, Anil Prahladan, Preethi George.
Software: Preethi George.
Validation: Preethi George.
Formal Analysis: Elizabeth Reshmi John.
Investigation: P Rema, Elizabeth Reshmi John.
Resources: P Rema, SuchethaSambasivan, Sivaranjith J, Anil Prahladan, Preethi George.
Data Curation: Elizabeth Reshmi John, Aswathy G Nath, Vijayshanthi J.
Writing—original draft: Elizabeth Reshmi John, P Rema.
Writing—review and editing: P Rema, SuchethaSambasivan, Sivaranjith J.
Visualisation: P Rema, SuchethaSambasivan, Sivaranjith J.
Supervision: P Rema, SuchethaSambasivan, Sivaranjith J, AnilPrahladan, Preethi George.
Project Administration: P Rema.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Aletti GD, Gostout BS, Podratz KC et al (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. GynecolOncol 100:33–37Google Scholar
- 3.Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953CrossRefGoogle Scholar
- 5.Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750Y755Google Scholar
- 16.Chang SJ, Bristow RE (2012) RyuHS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 19(13):4059–4067. https://doi.org/10.1245/s10434-012-2446-8 CrossRefPubMedGoogle Scholar